A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis
NCT ID: NCT04368806
Last Updated: 2025-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
140 participants
INTERVENTIONAL
2021-05-26
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis
NCT03990805
Clinical Trial to Evaluate Efficacy and Safety of JOINTSTEM in Patients With Degenerative Arthritis
NCT02658344
Investigator Initiated Trial to Evaluate Cartilage Regeneration by Arthroscopy After JOINTSTEM Administration
NCT04821102
Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis
NCT02805855
Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee
NCT02544802
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* Visit 1 (Week -7) - Screening
* Visit 2 (Week -5) - Baseline and Randomization (Lipoaspiration)
* Visit 3 (Week 0) - Treatment (Intra-articular injection)
* Visit 4 (Week 4) - 4 weeks follow-up
* Visit 5 (Week 12) - 12 weeks follow-up
* Visit 6 (Week 24) - 24 weeks follow-up
* Visit 7 (Week 36) - 36 weeks follow-up
* Visit 8 (Week 48) - 48 weeks follow-up (End of Study)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
JointStem
Autologous Adipose tissue derived Mesenchymal Stem Cells(AdMSC)
JointStem
Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
Placebo
Normal Saline with Autologous Serum
Placebo Control
Normal Saline with autologous Serum
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
JointStem
Autologous Adipose tissue derived Mesenchymal Stem Cells (AdMSC)
Placebo Control
Normal Saline with autologous Serum
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Subject who had osteoarthritis of knee diagnosed (according to the clinical and American College of Rheumatology Criteria)
3. Subject who has ≥ 45 on WOMAC function score at Screening and Baseline
4. Subject who has knee pain ≥ 70 mm for the study knee out of 100 mm on VAS (Visual Analog Scale) at Screening and Baseline
5. Subject who has radiographic evidence of grade 3 osteoarthritis in the study knee based on the Kellgren and Lawrence radiographic criteria
6. Subject who has a varus angle of 5 degrees or less confirmed through radiography
7. Subjects whose knee pain persists for at least 12 weeks (about 3 months) prior to Screening and does not improve symptoms with non-operative treatment options
8. Subject who is willing to discontinue all pain medications for osteoarthritis except rescue medication (acetaminophen \< 3.25 g per day) at least 72 hours prior to Screening and throughout the duration of study
9. Subject who is willing and able to give written informed consent for participation in the study
Exclusion Criteria
2. Subject judged by the investigator to have a history of clinically significant disease(s) (i.e., uncontrolled comorbid disease, kidney diseases, liver diseases, endocrine diseases, etc., but not limited to these diseases) that may affect the patient's participation in the study.
3. Subject who has any of following clinically significant diseases:
* Autoimmune diseases
* Paget's disease, ochronosis, acromegaly, hemochromatosis, or Wilson's disease
* Genetic diseases (hyperkinesia, collagen gene abnormality, etc.)
* Inflammatory joint disorders (e.g., rheumatoid inflammation)
* Infectious joint disorders (e.g., septic arthritis)
* Other joint disorders (e.g., gout, recurrent pseudogout, articular fracture, primary osteochondrosis, villonodular synovitis)
4. Subject who has any history of cancer and/or currently receiving treatment for a current cancer diagnosis.
5. Subject who is positive in pathogenic test (HIV, viral hepatitis, or syphilis)
6. Subject who has heart diseases (myocardial infarction, coronary artery bypass graft surgery, arrhythmia, or other serious heart diseases) or has history of heart diseases within 6 months prior to Screening
7. Subject who has received any intra-articular therapy in any joint within 6 months prior to Screening, or surgery on the relevant knee including articular endoscopic procedures within 6 months prior to Screening
8. Subject who has history of prolotherapy, or platelet rich plasma injection within 6 months prior to Screening
9. Subject who has received long-acting hyaluronic acid injection (e.g., Synvisc-One®, etc.) within 6 months prior to Screening
10. Subject who has history of stem cell therapy
11. Subject who has significant lab abnormalities for the following parameters (If the value is within 10% of the listed laboratory exclusion criterion value and the value is considered not to be clinically significant by the investigator, the subject can be considered for enrollment):
* Serum ALT and AST \> 2 x upper limit of normal
* Serum creatinine out of normal range
* PT/INR out of normal range
* Hemoglobin \< 10 g/dL for female subject and hemoglobin \< 11 g/dL for male subject
* Platelets out of normal range
12. Subject for whom the investigator judges the lipoaspiration can cause any problem
13. Subject who has history of local anesthetic allergy
14. Subject who has taken anti-inflammatory drugs (prescription and non-prescription NSAIDs), symptomatic slow acting drugs (glucosamine, chondroitin sulfate, diacerhein etc.), or oral steroids (prednisone etc.) within 14 days prior to Screening (however, those who undergo a 14-day wash-out period can participate.)
15. Subject who is an active drug/alcohol abuser
16. Pregnant or breast-feeding women, or women or men who are not using appropriate method of contraception (appropriate method includes hormones, bilateral tubal ligation, and barrier method with spermicide, and intra-uterine device for women and vasectomy and barrier method with spermicide for men; subjects should agree to use appropriate method)
17. Subject who is enrolled in any other clinical trials within 3 months from screening
18. Subject who received the COVID-19 vaccines within 1 week from Visit 2 (Lipoaspiration, baseline)
19. Subject who the principal investigator considers inappropriate for the study due to any other reasons than those listed above
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Nature Cell Co. Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
TriWest Research Associates
El Cajon, California, United States
BioSolutions Clinical Research Center
La Mesa, California, United States
Neurovations Research
Napa, California, United States
Newport Therapeutics
Newport Beach, California, United States
Source Healthcare
Santa Monica, California, United States
Keimyung University Dongsan Hospital
Daegu, Korea, South Korea
Kyung Hee University Medical Center
Seoul, Korea, South Korea
Kyung Hee University Hospital At Gangdong
Seoul, Korea, South Korea
Smg-Snu Boramae Medical Center
Seoul, Korea, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Arthur R. Mabaquiao, M.D.
Role: primary
Richard Paicius, M.D.
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JS-OAP3-US01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.